SkyCell Valuation, Funding & Investors
SkyCell is valued at $635M as of June 2024.
Last SkyCell valuation
$635M
Series D · Jun 2024
Last SkyCell funding round
$59M
Series D · Jun 2024
Cumulative funding SkyCell raised
$215M
across 4 funding rounds
Key investors in SkyCell
Catalyst
M&G Investments
MVM Life Science Partners
Tybourne Capital Management
DisruptAD
![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 20 20"><rect fill="%23e5e7eb" width="20" height="20" rx="4"/></svg>)
CC Industries
About SkyCell
SkyCell is a Zug, Switzerland-based provider of smart temperature-controlled containers for pharmaceutical logistics. The company equips units with real-time monitoring sensors compliant with GDP standards for vaccines and biologics. SkyCell serves Novartis, Pfizer, and Roche with reusable Reefers tracking temperature from -80°C to +25°C. Its Matrix platform prevents excursions through predictive alerts and serves routes across Europe and North America.
Founded
2013
HQ
ZurichWebsite
Status
Privately held
Customer focus
B2B
Revenue model
Usage-based, Subscription
Valuation
$635M (Jun 2024)
SkyCell Valuation
SkyCell is currently valued at $635M, based on its Series D in June 2024.
The $59M round included Catalyst, CC Industries and Tybourne Capital Management.
SkyCell's valuation has grown 1.1x from $600M at its Series D in October 2023 to $635M in June 2024, across 2 priced rounds.
SkyCell valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Jun 2024 | Series D | $635M |
| Oct 2023 | Series D | $600M |
SkyCell Funding History
SkyCell has raised a total of $215M across 4 funding rounds.
SkyCell's first fundraising round was a $64M undisclosed-stage round in April 2020. The most recent completed round was a $59M Series D in June 2024.
SkyCell funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Jun 2024 | Series D | Catalyst; CC Industries; Tybourne Capital Management | $59M | $635M | SkyCell is a Swiss-based deeptech company specializing in temperature-controlled smart containers and logistics software for pharmaceutical cold chain transport, including vaccines, cancer treatments, diabetes care, and diagnostic solutions. Its proprietary hardware reduces CO2 emissions by over 50% compared to competitors, complemented by the SkyMind platform that provides real-time visibility, automation, and optimization for supply chain decisions on risk, cost, and emissions. The company transports $2.5 billion worth of pharma goods, with 50% annual growth, and has expanded into selling components like smart thermometers. SkyCell closed its $116 million Series D funding round in June 2024, comprising a $57 million equity investment from Catalyst (M&G Investments’ purpose-led strategy) followed by $59 million from Tybourne Capital Management and CC Industries (CCI), the Crown family holding company. This extension elevated the company's post-money valuation to $635 million, higher than the prior 2023 tranche. Bosun Hau from Tybourne joined the board. The funds will support global expansion, particularly in the US, Asia, Americas, and EMEA, fleet size increases for decarbonization, and commercialization into adjacent pharma segments beyond core cold chain packaging. SkyCell positions itself as a technology partner for the pharma industry's growth amid blockbuster biologics and sustainability pressures, where over 70% of shipments use one-way solutions facing future disposal fees. Total funding raised to date stands at $235 million. |
| Oct 2023 | Series D | Catalyst (lead); M&G Investments (lead) | $57M | $600M | SkyCell is a Swiss deeptech startup revolutionizing the pharmaceutical supply chain with smart, reusable hybrid containers that maintain precise temperature control for transporting high-value biologics like vaccines, cancer treatments, diabetes care, and diagnostic solutions. Its proprietary SkyMind software platform provides real-time end-to-end visibility, CO2 impact prediction, sustainable route planning, and reduces waste by replacing single-use packaging, aligning with the industry's shift to CO2-neutral logistics. The company operates a global network of service centers to deliver containers within 24 hours at manufacturing hubs. On October 31, 2023, SkyCell raised $57 million (CHF 50 million) in an equity round led by Catalyst, the purpose-led private assets strategy of M&G Investments managing $6 billion, at a post-money valuation of $600 million. This funding follows prior raises totaling around $133 million, including $62 million and $35 million rounds from insurance companies, Middle East financiers, and healthcare specialists. The capital supports accelerated global expansion, increased container production, and network growth amid 55% compound annual growth over the prior three years, with normal growth rates of 40-50% post-pandemic. At the time of the round, SkyCell transported over $1.5 billion in pharmaceutical goods monthly, equivalent to hundreds of millions of doses, though this represents goods value rather than company revenue. Praveg Patil, Deputy Head of EMEA Investments at M&G Catalyst, joined the board, highlighting the investment's focus on climate solutions and healthcare impact. Dr. Remo Gerber was appointed CFO, bringing experience from Gett and Groupon EMEA. SkyCell's traction underscores its role in decarbonizing pharma logistics, reducing emissions and expediting life-saving drug delivery. A subsequent June 2024 extension raised $59 million from Tybourne Capital Management and CCI at a $635 million valuation, bringing the combined Series D to $116 million and expanding into adjacent pharma segments and markets like the US and Asia. |
| Oct 2021 | Series C | DisruptAD (lead); SHUAA Capital | $35M | - | SkyCell is a Swiss pharmaceutical air cargo container manufacturer that designs and produces IoT-connected containers for transporting temperature-sensitive pharmaceutical products. The company's solution combines hardware—reusable, temperature-controlled containers capable of maintaining precise conditions from standard refrigeration to -80°C for deep-frozen products—with a SaaS platform called SECURE that provides end-to-end shipment visibility and automated compliance approval for pharmaceutical companies. In October 2021, SkyCell closed a Series C funding round of $34.8 million (CHF 32 million) led by DisruptAD, the venture arm of Abu Dhabi's ADQ sovereign wealth fund, with participation from SHUAA Capital (a UAE publicly-listed asset management firm), China-based and Zurich-based family offices, and follow-on funding from existing investor Mobiliar, Switzerland's oldest private insurance company. The funding was designated for sales team expansion, conversion of a growing pipeline of pharmaceutical and biotech clients, and further development of hardware and software offerings. By the time of the Series C round, SkyCell had achieved significant traction, with revenue growing 60% year-on-year in the 2020/21 period and a documented failure rate of less than 0.1% across nearly one billion data points—substantially outperforming the industry-standard acceptance failure rate of 4 to 12%. The company had expanded its headcount by 45% since its April 2020 venture round and established service centers across San Francisco, Philadelphia, Seoul, Rome, Toronto, Tokyo, and Ireland, along with partnerships with major airlines including Qatar Airways, Saudi Cargo, KLM Airfrance, Korean Air, Virgin Atlantic, and ANA, as well as logistics providers DB Schenker and DSV. The company gained prominence for producing specialized containers for the BioNTech and Pfizer COVID-19 vaccine supply chain, positioning it as critical infrastructure for global pharmaceutical logistics during the pandemic. |
| Apr 2020 | Undisclosed stage | MVM Life Science Partners (lead); Swiss Entrepreneurs Fund; Banque Cantonale de Genève | $64M | - | SkyCell is a Swiss technology company developing data-driven, temperature-controlled containers for the pharmaceutical industry, focusing on safe transport of vaccines, biotech drugs, and other pharma products without active refrigeration to lower costs and reduce damage. In April 2020, it raised CHF 62 million (approximately USD 62-63.9 million) in a massively oversubscribed growth financing round led by MVM Partners LLP (MVM Life Science Partners), with participation from a leading Swiss insurance company, a consortium of family offices, and existing investors including the Swiss Entrepreneurs Fund managed by Credit Suisse and UBS, and the growth fund of Banque Cantonale de Genève (BCGE’s Capital Transmission SA). The funds were allocated to expand SkyCell’s global footprint, particularly in the US and Asia, and to grow its container fleet in response to rising demand from pharmaceutical companies for secure supply chains. The round coincided with strong early traction, as SkyCell's sales tripled in Q1 2020 compared to the prior year, amid heightened attention to pharma supply chains due to the COVID-19 pandemic, which underscored the need for reliable vaccine delivery. CEO Richard Ettl highlighted significant growth, with more pharma firms selecting SkyCell to mitigate risks under time pressure. This 2020 investment was part of SkyCell's broader funding history, preceding later rounds such as a $57 million equity raise in October 2023 at a $600 million valuation led by Catalyst (M&G Investments), bringing total funding to around $133 million at that point, and a $116 million Series D in 2024 with investors like Tybourne Capital Management and CC Industries. By 2023, SkyCell was transporting $1.5 billion in pharma products monthly, with 40-50% growth rates, and later protected over $2.5 billion monthly, emphasizing sustainability with CO2 reductions. |
Who has invested in SkyCell?
9 investors have backed SkyCell across its funding rounds, including Catalyst, M&G Investments, MVM Life Science Partners, Tybourne Capital Management, DisruptAD and CC Industries.
Lead investors include Catalyst, M&G Investments, DisruptAD and MVM Life Science Partners.
SkyCell Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
 Dublin | 2 | Lead | Oct 2023 | |
 London | 1 | Lead | Apr 2020 | |
| CC Industries |  Chicago, IL | 1 | Participant | Jun 2024 |
 Hong Kong | 1 | Participant | Jun 2024 | |
 Dubai | 1 | Participant | Oct 2021 | |
| London | 1 | Lead | Oct 2023 | |
| Zurich | 1 | Participant | Apr 2020 | |
This data is available for Pro users. Sign up to see all 9 SkyCell investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by SkyCell
SkyCell has acquired 1 company to date.
Last acquisition by SkyCell was on December 20th 2024. SkyCell acquired Validaide for undisclosed valuation.
Latest Acquisitions by SkyCell
| Description | Validaide is a digital platform headquartered in Denver that collects and manages supplier data for capabilities and lane risk assessment in logistics. It serves freight brokers and shippers by aggregating carrier compliance records, insurance details, and performance metrics from FMCSA databases. The platform processes data for over 1 million carriers across North America. |
| HQ Country |  |
| HQ City | Amsterdam |
| Deal Date | 20 Dec 2024 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all SkyCell acquisitions and their M&A valuation multiples. Start Free Trial | |
SkyCell Competitors
SkyCell competitors include listed companies like CE Info Systems and KSEC Intelligent Technooogy, and private ones like Tive, YH Global, DNAnexus and proteanTecs.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Boston, MA | Private | $25M | - | $500M | - | |
 Shenzhen | Private | - | - | $1B | - | |
| San Francisco, CA | Private | - | - | $600M | - | |
 Haifa | Private | $60M | - | $600M | 10.0x | |
 India | Publicly listed | $49M | $20M | $508M | 8.7x | |
| China | Publicly listed | $298M | ($9M) | $480M | - |
SkyCell Public Comps
SkyCell is still privately-owned, but its public comps include Posti Group, New Trend International Logis-Tech, Yuil Robotics, Aramex, Sercomm, SOPHiA Genetics, Singapore Post, Aquila Romania, Veradigm and Intelligo Technology.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $1.7B | $208M | 0.7x | 0.7x | 5.8x | 5.3x | |||
| $352M | $42M | 1.4x | - | 11.9x | - | |||
| $27M | ($16M) | 21.9x | - | (35.8x) | - | |||
| $1.7B | $148M | 0.6x | 0.6x | 7.3x | 6.1x | |||
| $1.7B | $84M | 0.5x | 0.4x | 10.0x | 8.9x | |||
| $77M | ($65M) | 8.8x | 7.5x | (10.4x) | (18.8x) | |||
| $295M | $79M | 1.9x | 1.8x | 7.0x | - | |||
| $643M | $40M | 1.0x | 0.8x | 16.1x | 16.2x | |||
This data is available for Pro users. Sign up to see all SkyCell competitors and their valuation data. Start Free Trial | ||||||||
Common questions about SkyCell
| When was SkyCell founded? | SkyCell was founded in 2013. |
| Where is SkyCell headquartered? | SkyCell is headquartered in Zurich, Switzerland. |
| Is SkyCell publicly listed? | No, SkyCell is a private, VC-backed company. |
| What is SkyCell's valuation? | SkyCell was last valued at $635M in its Series D in June 2024. |
| How much funding has SkyCell raised? | SkyCell has raised $215M across 4 funding rounds. |
| What was SkyCell's last funding round? | SkyCell's last funding round was a $59M Series D in June 2024. |
| Who are SkyCell's investors? | SkyCell's investors include Catalyst, MVM Life Science Partners, CC Industries, Tybourne Capital Management, SHUAA Capital, M&G Investments, Swiss Entrepreneurs Fund, DisruptAD and Banque Cantonale de Genève. |
| Which companies are comparable to SkyCell? | Companies comparable to SkyCell include Tive, YH Global, DNAnexus, proteanTecs, CE Info Systems and KSEC Intelligent Technooogy. |
| How many companies has SkyCell acquired? | SkyCell has acquired 1 company, including Validaide. |
See companies similar to SkyCell
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.